Literature DB >> 6587932

Complete remission in a patient with acute myelogenous leukemia treated with leukocyte alpha-interferon and cimetidine.

J Ankerst, R Fäldt, P G Nilsson, P Flodgren, H O Sjögren.   

Abstract

A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO. During therapy there was a gradual decrease of bone marrow myeloblasts down to 9% and a normalization of peripheral white blood cells. The treatment was discontinued after 6 weeks because of increasing fatigue and anorexia. The general condition improved greatly during the following weeks and the patient entered complete remission, which has continued for 6 months so far. In the course of therapy there was a gradual appearance of antibodies showing a selective binding capacity to autochthonous leukemic cells with no tendency to increased binding to remission cells. The aim of this report is to stimulate a further evaluation of this form of therapy in additional AML patients whenever this might be justified as an alternative to conventional chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6587932     DOI: 10.1007/bf00205501

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  Immunotherapy of human acute leukemia: antibody response to leukemia-associated antigens.

Authors:  M A Baker; J A Falk; R N Taub
Journal:  Blood       Date:  1978-09       Impact factor: 22.113

2.  Remissions after exchange transfusions in acute leukemia. On the possible antileukemic properties of normal blood. Historical notes and recent reflections.

Authors:  M Bessis; J Bernard
Journal:  Blood Cells       Date:  1983

3.  Interferon in acute myelogenous leukaemia: a preliminary report.

Authors:  A Z Rohatiner; F Balkwill; T A Lister
Journal:  Haematol Blood Transfus       Date:  1983

Review 4.  Unexpected remissions in acute leukemia.

Authors:  J Bernard; M Bessis
Journal:  Blood Cells       Date:  1983

5.  Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy.

Authors:  C H Granatek; K Ezaki; E M Hersh; M J Keating; S Rasmussen
Journal:  Cancer       Date:  1981-01-15       Impact factor: 6.860

6.  Human leukocyte interferon and cimetidine for metastatic melanoma.

Authors:  S Borgström; F E von Eyben; P Flodgren; B Axelsson; H O Sjögren
Journal:  N Engl J Med       Date:  1982-10-21       Impact factor: 91.245

7.  125I protein A: applications to the quantitative determination of fluid phase and cell-bound IgG.

Authors:  J J Langone; M D Boyle; T Borsos
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

8.  A 125I-protein A-binding assay detecting antibodies to cell surface antigens. Evidence for the presence of specific antibodies against leukemia-associated antigens in human leukemias.

Authors:  R Fäldt; J Ankerst
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Interferon therapy in myelomatosis.

Authors:  H Mellstedt; A Ahre; M Björkholm; G Holm; B Johansson; H Strander
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

10.  Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine.

Authors:  P Flodgren; S Borgström; P E Jönsson; C Lindström; H O Sjögren
Journal:  Int J Cancer       Date:  1983-12-15       Impact factor: 7.396

View more
  4 in total

1.  Demonstration of antibodies binding to autologous and allogeneic leukemic cells in childhood ALL. Evidence for a common ALL antigen(s).

Authors:  R Fäldt; J Ankerst; S Garwicz
Journal:  Blut       Date:  1986-06

Review 2.  Cimetidine as an immune response modifier.

Authors:  R Hast; P Bernell; M Hansson
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.

Authors:  Meng-Zhu Shen; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Xiao-Su Zhao; Ya-Zhen Qin; Ying-Jun Chang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Dong Mo
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

4.  Antibiotic and glucocorticoid-induced recapitulated hematological remission in acute myeloid leukemia: A case report and review of literature.

Authors:  Xiao-Yun Sun; Xiao-Dong Yang; Xiao-Qiu Yang; Bo Ju; Nuan-Nuan Xiu; Jia Xu; Xi-Chen Zhao
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.